@article{527faa1ca9204129a2f22b2803d4a8ef,
title = "Migraine and olcegepant - Authors' reply",
author = "Ho, {Tony W.} and Ferrari, {Michel D.} and Dodick, {David W.} and James Kost and Paul Winner",
note = "Funding Information: TWH and JK are employees of Merck and own stock or stock options in Merck. MDF has received grants and consultancy or industry support from Almirall, Coherex, Colucid, Eisai, GlaxoSmithKline, Linde, MAP, Medtronic, Menarini, Merck, Minster, Pfizer, and St Jude, and independent support from NWO, NIH, European Community FP6, Biomed EC, the Dutch Heart and Brain Foundations, and LUMC. His spouse owns stock in Merck. DWD has received honoraria from and has consulting agreements with Allergan, Pfizer, Merck, GlaxoSmithKline, Endo, OrthoMcNeil, Coherex, MAP, Neuralieve, Addex, Solvay, Eli Lilly, Neuraxon, Minster, HS Lundbeck, and Kowa, and has research grants from AstraZeneca, Medtronic, St Jude, and Advanced Neurostimulation Systems, and independent support from NINDS and Mayo Clinic. PW has received grant, consultancy, or industry support from Allergan, Forest, GlaxoSmithKline, Merck, Minster, OrthoMcneil, Pfizer, and Wyeth.",
year = "2009",
doi = "10.1016/S0140-6736(09)60599-7",
language = "English (US)",
volume = "373",
pages = "1003--1004",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9668",
}